macists can playa significant role in the prevention and management of PIS.
Data Sources
A literature review wasperformed viaMEDLINE (1950-July 1,2009) and International Pharmaceutical Abstracts (1970-June 2009)searches usingthe termspost-thrombotic syndrome, post-phlebitic syndrome, deep vein thrombosis, and compression stockings. We reviewed English-language publications, including randomized controlled trials, meta-analyses, case reports, and literature reviews,and selected publications deemed most clinically relevantto the topicof PIS.
Epidemiology HOWCOMMON IS PTS?
PIS is the most common complication of DVT, with symptoms occurring in up to half of patients following a first episode of symptomatic DVT, typically within the first 2 years. Most studies have reported an overall incidence of 20-50% for PIS ,5.10 but differences in the definition of PTS, diagnostic modalities, and PTS scales have limited a more precise estimation of the trueincidence.
The reported incidence of PIS following asymptomatic DVT is less clear.While some studies have shown that as many as 25-33% of patients with asymptomatic DVT de-velopPIS, other investigations havefoundeitherlow rates of PTS or no significant difference in the ratesof PTS with asymptomatic proximal DVT or calf DVT,compared with no DVT.S,II,I2 Mostof thesestudies examined postoperative orthopedic surgerypatients,were limitedby smaller sample sizes, and differed in the definition of PTS and the methods employed for the diagnosis of DVT.
WHATIS THE EFFECT OF PTSON QUALITYOF LIFE?
BecausePTS symptoms are typically more severe with standingor physical activity, PTS has been associated with a reduced QoL. For example, Kahn et al," studied both validated generic and venous disease-specific QoL measures. They found that of 387 patients with acute DVT, those who developed PTS had lower scores and significantly less improvement in QoL when assessed 2 years following the index event. QoL scores were negatively correlated with the severity of PIS symptoms. PTS was the only independent predictor of venousdisease-specific QoL, suggesting that the development of PIS may have the largest effect on QoL afterDVT.Additionally, multiple studies have demonstrated that patients with PIS have a significantly poorer QoL than DVT patients without PIS or patients withotherforms of chronic venousdisease. 2.14,1S
WHATIS THE COSTOF PTS?
The estimated healthcare costs of treating PIS add significantly to the cost of treating DVT.The annual cost of PIS in the US has been estimated at approximately $200 million,with costs over $3800 per patient in the first year alone." Annual per-patient cost increases with disease severity.P-" Venous ulceration is the mostexpensivecomplication, costing nearly an additional $8000 per patient." The indirectcosts of PIS are significant as well. It is estimated that over one quarterof the 170,000 cases of venous stasis syndrome are a resultof PIS and that up to 2 million workdays are lost per year due to complications related to leg ulcers.P"
HOW DOES PTS DEVELOP?
Despite ongoing investigations intothe pathophysiology of PIS, the mechanisms and processes leading to its developmentare not entirely clear. Inflammatory mediators and the acute thrombus itselfmay damagethe venouswall and cause valvular incompetence which, in turn, leads to venous hypertension and reducedcalf muscleperfusion with subsequent altered muscle metabolism.P-" Increased tissue permeability presentin PIS likelyresults from a combination of increased venouspressure augmented by angiostatic chemokines.Thus, as vessel diameter increases due to valvular incompetence and inflammatory-mediated chemokine changes, fluid accumulates and permeability markedly increases." Takentogether, these processes lead to edema, tissuehypoxia, and in severe cases,lipodermatosclerosis and ulceration ( Figure 1 ).5,\1
WHATARE RISKFACTORS FOR PTS?
The location and size of the initial DVT may predict the risk of PIS.6 For example,proximal DVT has beenassociated with a 30% higher risk of developing PTS compared with distal DVT,1O In addition, ipsilateral DVT increases the risk of PTS 6to 1O-fold. 6,\1,22 This higher risk may reflect the additional damageof recurrent thrombosis on the venous valves and endothelium. The presenceof residual thrombus on ultrasound has not been defmitively shown to increase the risk ofPIS. 14, 23 Althoughr:either age nor sex has been shown to definitively increase the risk of PTS,lO.14,22,24.26 obesity (body mass index~30 kg/m'), which is a major risk factor for DVT, is associated with an increased risk and severity of PTS. This higher risk may be due to increased venous pressure promoting venousreflux in already compromised veins in the setting of chronic debilitation and poor muscle function. 8,10.14,24 The presence of an identified thrombophilia is associated with an increased risk of venousleg ulcers but does not increase the risk of PTS,10,22,27 26 reported that patients with DVT with subtherapeuticanticoagulation (INR <2.0) more than 50% of the time duringtheirfirst3 months of warfarin treatment had an increased risk of developing PTS during the 5yearfollow-up period(OR2.71).Importantly, tightINR control may mitigate the risk of PTS. When comparingpatients who had a subtherapeutic INR over 30% of the time with those whose INR was therapeutic over 30% of the time,the OR for developing PTS was 1.89. When patients' INRs were outside the therapeutic range90% of the time,the OR for developing PTS increased to 3.69.
Since pharmacists often provide anticoagulation management and monitoring, they are uniquely positioned to identify patientsat risk for PTS and can help to ensure that patients are educated on the importance of maintaining therapeutic anticoagulation to prevent complications of DVT,such as PTS.
Diagnosis
Typically, PTS is characterized by lower extremity swelling and pain.These symptoms are oftenworse with~-tivity and improved with rest or elevation of the affected limb.Other symptomsincludecramping,tingling, and itching. On examination, patients with PTS may have edema, erythema,varicoseveins, and eczema; severe cases may be associated with chronic ulcers," When a patient presents with these unilateral symptoms, has a history of DVT, and new or recurrentDVT is excluded,a diagnosisof PTS may be madec1inically.S,28 Ideally, the diagnosis of PTS shouldbe deferred until 3-6 months afterthe index DVT,as symptoms due to acuteDVT may takethislongto completely resolve.
There are now 4 clinical scoring systems that may be helpful for the diagnosis of PTS. These include Widmer staging," Villalta scale," Ginsberg measure.i'-" and Clinical-Etiologic-Anatomic-Pathophysiologic (CEAP) classification" ( Table 1 ).There is no clear advantageof using one of these scales over the others. Both the CEAP and Widmer scales are more general classifications and may be used in evaluating both PTS and chronic venous disease, while the Villaltascale and Ginsberg measure are specific for PTS. Although the Villaltascale appears to be gaining in use and popularity, none of these scales has undergone rigorous validation.Differences in the interrater reliability of these scales may be one of the reasons why reported rates of PTS vary in publishedstudies." Documenting valvular incompetence by Doppler ultrasonographyor by plethysmography is not necessaryif typical PTS signs and symptoms are present in a patient with a historyof DVT. If valvular incompetence is identifiedby imaging without the presence of typical signsand/orsymptoms of PTS, a diagnosis of PTS should not be made,28,34 as many patients with a history of DVT willhave evidence of valvular incompetency on imaging studies. A recent article calls for an established uniform definition of PTS to provide greater validity between researchers and practical use for clinicians,"
Prevention DVT PREVENTION
Arguably, the most effective way to prevent PTS is to prevent DVT from occurring. We now have a number of well-designed, randomized studies demonstrating that pharmacologic prophylaxis effectively reduces the risk of DVT and pulmonary embolism in patients at risk," Unfortunately, despite thesehigh-quality data, many hospitalized patients are either not correctly identified as being at risk (and thus do not receive appropriate thromboprophylaxis) or receivea prophylaxis regimen that is not supported with current recommendations (eg, aspirin alone or mechanical devices alone when a pharmacologic agent is more appropriate and there is no appreciable bleeding risk).36,37 All providers, including nurses, pharmacists, and physicians, should be engaged in recognizingat-risk patients and ensuringthat appropriate prophylaxis is orderedand administered in a timelyfashion. One method of preventing the development of PTS is the use of elastic compressionstockings(ECS). ECS provide graduated levels of compression(highest pressure at the ankle,lowestpressure at the knee or thigh) to assist the calf muscle and improve tissue circulation, although the exact mechanism is not well understood.s-" In general,the lower strength stockings are used for prevention or treatment of minor venous conditions, and the higher strength are used for more severevenousconditions ( Table 2) .
What Is the Evidence?
The benefitof using ECS for the prevention of PTS was first seenin a small number of observational trialS. 34, 40, 41 Four randomized, controlled trials have beenpublished withconflicting results regarding the efficacy of ECS in the prevention of PTS (Table 3) Each of these trials has limitations. The 2 positive studies were nonblinded, contrasted with the Ginsberg trial, which utilizeda placebo stocking (stocking 1-2 sizes too large,thus producing no hemodynamic effect)for comparison. Some state that the use of a placebo stocking may haveactually been a confounder, sinceit is possible the placebo stocking couldhaveprovided someunknown degree of compression," Finally, the Aschwanden trialwas actually underpowered for its primary outcome of detecting postthrombotic skinchanges.
A meta-analysis of the Brandjes, Ginsberg, and Prandoni trials by Kolbach et al. 44 reported that the use of ECS significantly reduced the incidenceof all PTS (OR 0.31; 95% CI 0.20 to 0.48) and of severe PTS (OR 0.39; 95% CI 0.20 to 0.76).A meta-analysis by Giannoukas et al. 45 also found that the use ofECS reduced the risk ofPTS (RR 0.52; 95% CI 0.40 to 0.67). The Giannoukas meta-analysisincluded the above3 trials plusan additional 37-patient trialthatrandomized patientsto either bed rest and no compression or early ambulation (plus either Unna boot bandages or 30-to 40mm Hg strength compression stockings) for 9 daYS. 46 Limitations of both meta-analyses were the lack of a uniform definitionof PTS, varying compressionregimens (specifically with regard to strength,timing, and duration), varying assessments of adherence, and varyingdurationof anticoagulation.Further, the trial" included in the second meta-analysis assessed early ambulation combined with compression therapy as a preventive strategy, so we are unableto assess the sourceof treatmentbenefit.
A large, randomized, multicenter controlled trial in progress mayclarifytheseissues," The SOX trialinvestiga- The compression strength of stockings used in these randomized trials ranged from 20 to 40 mm Hg.22,3I,4Z, 43 The clinical trials using 30-to 4O-mm Hg strength stockings demonstrated the most efficacyin reducing the risk of PTS and is reflected in current recommendationsfor PTS prevention" (Appendix I). However,currently, there are no data directly comparing the efficacy of different strengths of ECS for PTS prevention and further studies are needed to determinethe minimumeffectivestrength.
What Is the Timing and Duration of ECS Therapy?
The optimal time of initiation and durationof ECS therapy after a diagnosis of DVT remaincontroversial. No published studiesto date have specifically evaluatedthe timing of stocking application on the incidence of PTS. The randomized controlled trials citedaboveemployed ECS at various time points(immediately uponDVT diagnosis up to 1 y afterdiagnosis).ll,J1,42,43 One randomized trialassessed theeffects of earlyversus laterapplication of ECS on veinrecanalization following DVT. 49 Patients wereprescribed 255-325 mm Hg ECS within the first 14 days after the initiationof DVT treatment. FIfty-two patients completed 90 daysof fol-lOW-Up. In the earlycompression therapy group,82% of occluded venoussegments were completely recanalized at 90, days, as comparedwith 60% completerecanalization in the control group(OR0.27;95% CI 0.07 to 0.89).No patients in either group demonstrated PTS symptoms at 90 days (method ofPTS diagnosis notdefined). However, PTS was a secondaryendpoint, with the number of patients too small and studyduration too shortto makea definitive assessment.
The early application ofECS may have opposingeffects on adherence. Patients usually experience the most leg pain and swelling in thefirstfew weeks following DVT diagnosis and may associate improvement in their symptoms withthe use of ECS. The randomized trials that applied ECS early (within thefirstmonthfollowing DVT diagnosis) had excellent adherencerates (76-93%), 22, 42, 43 The one trial that employeda lateapplication ofECS (at 1 y following DVT diagnosis) did not report adherencedata," However,if patients have significant lower extremityswellingimmediately following DVT diagnosis, they may require a different size stockingearly in therapy as opposed to later in therapy,requiring additional purchases of stockings. Also,the earlyleg pain and swelling may actually prohibitmany patients from usingthe stockings.
Regarding the duration of ECS, trial data demonstrate thattheincidence ofPTS is highest in thefirst2 yearsfollow-inga diagnosis of proximal DVTand doesnotchange appre-ciablyafter2 years. 22 ,42,43 Thesereports implythat compressiontherapy willlikely be beneficial at leastfor thisduration of time,although indefinite usemaybe reasonable in patients withongoing signs or symptoms ofPrS.
Consistent with current recommendations from the AmericanCollege of Physicians, the AmericanAcademy of Family Physicians, and the AmericanCollege of Chest Physicians (ACCP), providers should discuss PTS with and prescribe ECS for all patients within the first month following acute proximal DVT diagnosis, preferably with-Prevention and Management ofPostthrombotic Syndrome in the first 2 weeks after diagnosis, and continuing for a minimum of 2 years 48 ,50 Patientadherence is perceived to be a barrierto the routine use of ECS due to discomfort, difficultywith putting themon, and COSt. 51 Clinical trials,whichused varying definitions for "regular"use of ECS, reported adherence rates between 54% and 93%. 22,40.43 Althoughone might expect to see a lower rate of adherence outside the setting of a clinical trial,of 78 patients surveyed in routineclinical set- tings, 87% reported daily use of ECS.Sl Adherence rates are significantly lowerin patients withdistal DVT,as these patients generally havefeweror less severesymptoms.v" To improve patient adherence to ECS,providers mayprescribe knee-length ECS, similar to what was used in most clinicaltrials.Compared with thigh-length ECS, the kneelength products arejust as effective but may be much more comfortable for patients," Basedon the mechanism and designof the stockings, it is thought thatas long as the highest pressure is applied at theankle,the stocking willprovide the desired effectof reducing pain and edema,regardless of the location of theclot," As was thepractice in mostclinical trials,patients should be instructed to wearthestocking onlyon the affected leg during waking hours. 22,31.J8,39,43 Difficulty puttingon the stockingsis often a barrierto patientadherence," There areseveral things thatpatients can do to make thisprocess easier (Appendix I).
Cost was alsocitedas a perceived barrierto adherence," ECS 30-40 mm Hg can be purchased at most medical supply stores with a prescription; the average cost is approximately $40-50 per pair (results of an informal survey of local medical supplystores,May 18,2009), which may not be reimbursed by some third-party insurers.
There are other important itemsto rememberwhen prescribing ECS (Appendix I). Patients' ankleandcalfcircumferences shouldbe measured to obtainthe appropriate size stocking. For optimal accuracy, thesemeasurements should be taken in the earliestpart of the day when leg swelling'is minimal. The stockings shouldbe replaced every 6 months so that proper elasticity and, hence, efficacy is maintained. 22 Some have proposedthat exerciseand/orearly ambulation (withor withoutcompression therapy) following a diagnosis of DVT may help to reduce the risk of PIS. In one study, patients who received compression therapy plusearly mobilization had significantly lower Villalta scores 2 years post-DVT compared with patients who were prescribed bed rest and no compression therapy." Another study demonstrated that patients may continue to wear ECS during exercise,but that stockings will not necessarily helpto improve symptoms duringor causedby exercise, nor will they increase exercise capacity."
How can PTS Prevention with ECS Be Improved?
As providers, we shouldensurethat ECS are prescribed for all patients with proximal DVT to optimize PIS prevention efforts. Despiterecommendations from evidencebased guidelines, a survey conducted by Kahn et aU I revealed that onlyone third of 34 Canadian physicians routinely prescribeECS following DVT diagnosis,and only half prescribe the recommended strength stocking (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) .Recent data suggest thatratesof ECS prescription may not be higher in specialty anticoagulation providers." Pharmacists canimprove therateof ECSprescribing by initiating protocols andpolicies for prescribing ECS,so thatthis becomes standard practice across institutions. The pharmacistwhointeracts regularly with patients whohaveDVTis in the position to identify patients at riskforPTS andto recommend appropriate preventive therapy. The pharmacistcan alsoassistpatients in obtaining ECS and educating them in theirproperuse. By takingthis activerole,pharmacists can improve patient adherence to use of ECS,prevent PIS, and makea major impact on decreasing thislong-term complica-tionofDVT.
DOESUSINGABRINOLYTICS FOR ILIOFEMORAL DVT PREVENT PTS?
Patients withacute iliofemoral DVTappear to be at higher risk of developing severePTS.ss Although conventional treatment for iliofemoral DVT is a parenteral anticoagulant followed by warfarin, this therapy does not reliably lead to recanaIization of affected veinsegments." Studies investigating the use of systemic fibrinolytics in conjunction with unfractionated heparin(UFH) reported that vein patencyand valvefunction appeared to be bettercompared with the use of heparin a1one. S7 ,S8 In addition, meta-analysis data from 5 studies encompassing 110patients demonstrated thatthe incidenceof PTS was lower in patientswith DVT who were treated with streptokinase and UFH compared with those treated withUFH alone (425% vs 69.6%, OR 0.46,95%CI 0.21 to 0.99).59 These data,of course, arelimited by thesmaIl samplesizes,significant heterogeneity in the different study designs, the lackof a uniform definition of PIS, and incompletestudy follow-up."
In comparison, catheter-directed thrombolysis (CDT) is a methodby which a fibrinolytic agent is delivered viacatheterintoa clotwithin a thrombosed vein. Several recent trials have studied the benefit of CDT in iliofemoral DVT. Although different in study design and outcome measures, these trials reported thatin carefully selected patients, the use of COT as an adjunct to standard treatment (ie,a heparinoid and warfarin) improved venous patency and wasassociated withfewerlong-term symptoms of PIS .61.64 Forexample, a retrospective survey in patients withiliofemoral DVT reported thatpatients treated withCOTin addition to standard anticoagulation (n =68)hadsignificantly fewerPTS symptoms (p = 0.006) thandid thosetreated withanticoagulation alone (n = 30).62 Subsequently, the ACCP now recommends that CDT (or systemicthrombolysis ifCDT is unavailable) be usedin selectpatientpopulations (iliofemoral DVT,symp-tomsfor<14days,goodfunctional status, lifeexpectancy~l y,lowbleeding risk) forthepwposeof reducing acute symptomsandpostthrombotic morbidity," Treatment MECHANICAL Studies have employed various mechanical methods to treat PTS, including compression, elevation, and dressings (Table 4 ). Most authorshave focused primarilyon edema as a measurable outcome in response to PTS treatment." Physical compression methods include any type of circular pressure on the leg. Utilized techniques include adherent tape , Unna's pasteboot, ECS, and newervenous return assist devices, such as the Venowave. Although these treatments are frequently prescribed, their benefithas not been clearly established. A review of patients withWidmer stage I and IT PTSfound no benefit ofECS (30-40 mm Hg at the ankle) compared with placebo." In patients with severe PTS, intermittent pneumatic compression (lPe) did reduce symptom severity and increase blood oxygenation.":" Clinical guidelines reflect this research, and the ACCP suggests compression therapy for mild leg edema and IPC for severelegedema."
PHARMACOLOGIC
There are several pharmacologic treatments available for PTS-related edema and venous ulcers ( Table 4 ). Although none of these has proven safety and efficacy in large clinical trials, theymay provide symptomatic relief. Patients using pentoxifylline demonstrated significantly improved venous ulcerhealing at 6 months,"A meta-analysis of 11 randomized trialsevaluated and supported pentoxifyIIine's effectiveness (RR 1.56; 95%CI 1.14to 2.13),71 although notall trials reached statistical significance." A pentoxifyIline regimen of 400 mg 3 times daily waslargely uniform across the studies included in the meta-analysis," One study compared pentoxifylline 400mg 3 times daily with800mg 3 times daily and found no significant difference in ulcerhealing rates.
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Duration of therapy was not specifically studied and varied from as little as 6 weeks (orhealing of theulcer) to 6 months. According to themeta-analysis, pentoxifylline is well tolerated, withgastrointestinal upsetas the mostcommon adverse effect. Aescin (orescin), the main active component of horse chestnut, has antiinflammatory, vasoconstrictive, and vasoprotective properties"; it is primarily effective in the treatment of venousulcers. In a 12-week studyof patients with chronicvenous insufficiency, treatment with aescin50 mg twice daily reduced PTS symptoms similarly compared with ECS.'4 Rutosides (rutin),naturally occurring,yellowcrystalline flavonol glycosides, affect capillary permeability and havebeenstudied morein chronic venous insufficiency than in PTS specifically," When applied eithertopically or systemically, rutosides do appear to improve leg edema and bloodflow in these patients. 48 • 76078 For pharmacologic treatmentof PTS,the ACCPrecommends pentoxifylline 400 mg 3 times daily in conjunction withlocaIized careandcompressionor IPC devices for venous leg ulcers. For persistent venous ulcers, the ACCP recommends treatment with rutosides," Thereare currently no formal recommendations for using aescin as a treatment forPTS-related complications.
Pharmacists can helpin the treatment of PTS by making recommendations for appropriate pharmacotherapy and monitoring for drug interactions with any new therapy, as many of these patients may still be taking warfarin for treatment of theirDVT.
Upper Extremity PTS
The development of PTS after upper extremity DVT is less well studied than after lower extremity DVT,but the incidence appears to be approximately 15%overall,witha range reported in studiesbetween7% and 46%.79 No publishedtrialshaveevaluated the efficacy of compression devicesand/orvenoactive drugs in upperextremity PTS.We echo the recommendations of the 2008 ACCP guidelines against the use of preventive therapy for PTS in patients with upperextremity DVT. In patients withupperextremity PTS symptoms that do not resolve,elastic bandages or compression sleeves may providesome symptomrelief," Additionally, referring these patients to a lymphedema clinicmay be helpful.
Areas of Future Study
There are several areas where additional investigations and studies will help us to better understand how to prevent and treat PTS. First, the clinical scoring systems for diagnosis ofPTS have not been validated ( Table 1) .A validated diagnostic tool will improvethe qualityand uniformity of clinical trials and allow us to betterdefine and assess the impact of PTS on patients with DVT. Second, there are still unanswered questions regarding the optimal prevention of PTS. Although several trials have demonstrated the efficacyof ECS for PTS prevention, the minimum compression strength necessary and the optimal timing and duration of compression therapy remain unknown. We needdata on whether ECS are effective or even necessary for prevention of PTS following eitherasymptomatic or distal DVT. In addition,the role of fibrinolytic therapy in reducing PTS is still unclear. Finally, additional treatmentoptions for PTS with demonstrated safety and efficacy are needed, particularly in the areaof pharmacotherapy.
Summary
PTS is a commonand costly complication of DVT and significantly affects a patient's QoL. Acute DVT and the accompanying inflammation cause valvular incompetence and venous hypertension, which result in the pain,swelling, andvenous ulceration thatare associated withPTS.Preventiveefforts should be multifaceted, and we must not forget the importance of evidence-based DVT prophylaxis in patientsidentified as being at risk. Once DVT has occurred, we should ensureoptimal anticoagulation control, monitor for signs and symptomsof PTS, and provide appropriate preventive therapy. ECS,whenapplied within the firstfew weeksfollowing DVT and continued regularly for at least 2 years,are effective in preventing PTS. Fibrinolytic therapy for acuteiliofemoral DVT may be appropriate for carefully selected patients. Finally, if patients develop PTS,the diagnosis should be made based on clinical signs and symptoms; imaging is usuallyunnecessary. Treatmentof PTS includes pharmacologic agents, such as aescin or horsechestnut, rutosides, and pentoxifylline, and compression therapy and wound care for venous ulcers. Pharmacists have the opportunity to provide morecomprehensive antithrombotic management by providing education to all patients with DVT regarding PTS, recommending and/or prescribing appropriate preventive therapy,assisting patientsin obtaining and adhering to this therapy, and assisting providers withthe diagnosis and management of PTS.
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For a patientwho has had a symptomatic proximal DVT, we recommend the use of an elastic compression stockingwith an ankle pressuregradient of 30 to 40 mm Hg if feasible (Grade 1A). Compression therapy, which may includeuse of bandagesacutely, should be started as soon as feasible after startinganticoagulant therapy and should be continuedfor a minimumfor 2 years, and longerif patientshave symptomsof PTS.
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Compression stockingsshould be used routinelyto prevent postthrombotic syndrome, beginning within 1 month of diagnosisof proximal DVT and continuingfor a minimumof 1 year after diagnosis.
Elastic Compression Stockings
Explain PTS and begin ECS "as soon as feasible"within the first month following OVTdiagnosisand continuedfor at least 2 years.
Prescribea knee-length stocking(regardless of the locationof the DVT) worn only on the affectedleg during waking hours.
Preparethe patient with the following information:
prescription Is requiredfor the 30-to 40-mm Hg strength ECS replace ECS at least every 6 mo approximatecost of ECS list of local medicalsupplystores that stock the appropriate-strength ECS ECS should be sized to fit based on ankle and calf circumference measurements (sizingshould be done at the time of day when extremityis least swollen)
Tips for application of ECS:
If the patientcannottolerate wearingECSall day,havehimlherwearECSfor a fewhoursat a time,and gradually increase the amountof timewom.
Put ECS on first thing in the morningwhen extremityis least swollen. Do not allow wrinkles in the ECS.
00 not cut or alter ECS.
Never fold or roll down ECS.
Pts. with difficultybending to put on stockingsmay try assist devices such as rubber gloves (providesa better grip to pull ECS) or a stockingaid (stockingfits over a metal device, patient slides foot into stocking).
Pay attentionto manufacturer instructionsfor the ECS: wash and dry as directedto prevent shrinkage or damageto the stockings. Prevention and ManagementofPostthrombotic Syndrome farmaceuticos tienenla oportunidad de proveerun manejo antitromb6tico abarcador al educara los pacientes y proveedores de saludsobreel sfndrome post-tromb6tico. Tambien puedenrecomendar el tratarniento preventivo adecuado, ayudara los pacientes a obtenery cumplircon el tratarniento, y ayudara los proveedores de saluden el manejo de PTS.
ECS = elasticcompression
CONCLUSIONES: EI sfndorme post-tromb6tico es unacomplicaci6n cormin de DVT y puedemanifestarse con sfntomas cr6nicosy afectar negativamente la calidadde vida.Los proveedores de saluddebende ser proactivos en la prevenci6n de PTS y los farmaceutcos debende asumir un papelactivoen la prevenci6n 6ptimade DVT,identificar pacientes a riesgode PTS,aconsejar y manejar los tratarnientos preventivos. 
